These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 11060468)
21. CYP2C19 polymorphism and proton pump inhibitors. Klotz U; Schwab M; Treiber G Basic Clin Pharmacol Toxicol; 2004 Jul; 95(1):2-8. PubMed ID: 15245569 [TBL] [Abstract][Full Text] [Related]
22. Pharmacological properties of the gastric H(+)/K(+) ATPase inhibitor, AU-461. Cheon HG; Kim HJ; Mo HK; Lee BH; Choi J Pharmacology; 2000 Apr; 60(3):161-8. PubMed ID: 10754453 [TBL] [Abstract][Full Text] [Related]
23. Shortcomings of the first-generation proton pump inhibitors. Tytgat GN Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S29-33. PubMed ID: 11430506 [TBL] [Abstract][Full Text] [Related]
24. Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors. Shamburek RD; Schubert ML Gastroenterol Clin North Am; 1992 Sep; 21(3):527-50. PubMed ID: 1355465 [TBL] [Abstract][Full Text] [Related]
25. Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands. Kirchhoff P; Andersson K; Socrates T; Sidani S; Kosiek O; Geibel JP Am J Physiol Gastrointest Liver Physiol; 2006 Nov; 291(5):G838-43. PubMed ID: 16798725 [TBL] [Abstract][Full Text] [Related]
26. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Rost KL; Roots I Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169 [TBL] [Abstract][Full Text] [Related]
27. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340 [TBL] [Abstract][Full Text] [Related]
28. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Huang JQ; Hunt RH Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532 [TBL] [Abstract][Full Text] [Related]
29. Oxidation of R- and S-omeprazole stereoselectively mediated by liver microsomal cytochrome P450 2C19 enzymes from cynomolgus monkeys and common marmosets. Uehara S; Kawano M; Murayama N; Uno Y; Utoh M; Inoue T; Sasaki E; Yamazaki H Biochem Pharmacol; 2016 Nov; 120():56-62. PubMed ID: 27641812 [TBL] [Abstract][Full Text] [Related]
30. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis. Zendehdel N; Biramijamal F; Hossein-Nezhad A; Zendehdel N; Sarie H; Doughaiemoghaddam M; Pourshams A Arch Iran Med; 2010 Sep; 13(5):406-12. PubMed ID: 20804307 [TBL] [Abstract][Full Text] [Related]
31. BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. Kromer W; Postius S; Riedel R; Simon WA; Hanauer G; Brand U; Gönne S; Parsons ME J Pharmacol Exp Ther; 1990 Jul; 254(1):129-35. PubMed ID: 2164086 [TBL] [Abstract][Full Text] [Related]
32. The H+/K+-ATPase inhibitory activities of Trametenolic acid B from Trametes lactinea (Berk.) Pat, and its effects on gastric cancer cells. Zhang Q; Huang N; Wang J; Luo H; He H; Ding M; Deng WQ; Zou K Fitoterapia; 2013 Sep; 89():210-7. PubMed ID: 23742858 [TBL] [Abstract][Full Text] [Related]
33. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Robinson M Int J Clin Pract; 2005 Jun; 59(6):709-15. PubMed ID: 15924600 [TBL] [Abstract][Full Text] [Related]
34. [Endoscopic stage classification of peptic ulcer and characterization of the healing process by proton pump inhibitors]. Karasawa H; Miwa T Nihon Rinsho; 1992 Jan; 50(1):74-80. PubMed ID: 1347333 [TBL] [Abstract][Full Text] [Related]
36. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo. Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936 [TBL] [Abstract][Full Text] [Related]
37. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936 [TBL] [Abstract][Full Text] [Related]
38. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo. Shin JM; Homerin M; Domagala F; Ficheux H; Sachs G Biochem Pharmacol; 2006 Mar; 71(6):837-49. PubMed ID: 16405921 [TBL] [Abstract][Full Text] [Related]
40. Control of gastric acid secretion in health and disease. Schubert ML; Peura DA Gastroenterology; 2008 Jun; 134(7):1842-60. PubMed ID: 18474247 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]